This document provides knowledge assessment questions to support Level 1 learning materials, which focus on foundational biosimilar concepts and the connection between reference products, biosimilar products (also called biosimilars), and interchangeable biosimilar products (also called interchangeable biosimilars). These questions are intended to aid in teaching biosimilar content by facilitating discussion and understanding of biosimilars among students enrolled in health care-degree programs.

You may need to modify the questions or discussion responses to align with your specific health specialty or teaching needs. Refer to FDA’s website for additional information and other teaching resources on biosimilars.

**Knowledge Assessment Questions**

**What are biologics?**

Biologics are generally large, complex molecules that are made from living sources such as bacteria, yeast, and animal or plant cells. This makes biologics different from other medications, which are typically made from chemicals.

**Why can’t a biologic be copied exactly?**

Biologics, including reference products, biosimilars, and interchangeable biosimilars, are generally made from living organisms. The structures of biologics are generally more complex than those of conventional small molecule drugs and inherently contain many slight variations. Because they generally come from living organisms, and their structures are generally more complex than those of non-biologics, biologics are often more complicated to purify, process, and manufacture (Figure 1).

**Figure 1: Summary of manufacturing process for reference products and biosimilar products**

It is important for biosimilar manufacturers to understand and control sources of biological product variability. Biosimilar manufacturers design their manufacturing process so that the biosimilar is structurally and functionally similar to the reference product.

**What is a reference product and how is it related to a biosimilar?**

Biologics include reference products, biosimilars, and interchangeable biosimilars. A reference product is approved in a 351(a) application (i.e., a “standalone” application) that must contain all data and information necessary to demonstrate the safety, purity, and potency (i.e., safety and effectiveness) of the product.
A biosimilar is compared to and evaluated against a reference product to ensure that the biosimilar is highly similar to the reference product and that there are no clinically meaningful differences between the products. Biosimilar manufacturers then may rely on FDA’s determination of safety and effectiveness for the reference product. The rigorous approval process ensures that biosimilars can be expected to provide the same potential treatment benefits and potential side effects as their respective reference products.

How is the relationship between generic and brand-name drugs different than the relationship between biosimilars and reference products?
Both biosimilars and generic drugs are versions of original medicines that may offer patients more affordable treatment options. A main difference between biosimilars and generic drugs is that the active ingredients of generic drugs are generally made up of smaller, simpler molecules that are the same within each manufactured lot and between lots. Biologics generally cannot be copied exactly, because the products contain a mix of many slight variations of the same protein. Minor variations to the protein structure can occur naturally during the manufacturing process of biologics, as shown in Figure 2. Different colored diamonds depict examples of glycosylation that may occur during the manufacture of therapeutic proteins such as monoclonal antibodies. This mix of individual protein molecules with slight variation is observed between different lots during the manufacturing process for both reference products and biosimilars (also called lot-lot variation). For this reason, biosimilar manufacturers must demonstrate that their products have similar types and levels of variation compared to the reference product.

What is the purpose of a biological product’s core name and the 4-letter suffix?
Use of a shared core name indicates relationships among biological products, including biosimilars and interchangeable biosimilars. The unique 4-letter suffix is used to distinguish products that share a core name and facilitates safe use and pharmacovigilance. Health care professionals should include the suffix when ordering, prescribing, and dispensing biologics and when reporting adverse events to MedWatch, the FDA Safety Information and Adverse Event Reporting Program.

What benefits might biosimilars bring to patients and the health system?
Biosimilars may provide the following benefits to the patients: (1) More treatment options; (2) Increased access to medicines; and (3) Potentially lower cost of the biosimilar medicine.

Can biosimilars and interchangeable biosimilars be substituted for reference products by pharmacists?
Health care professionals can generally prescribe biosimilars and interchangeable biosimilars just as they would prescribe other medications. FDA-approved interchangeable biosimilars may be substituted for the reference product without the intervention of the prescribing health care provider, subject to state laws. State laws that address substitution of biologics at the pharmacy level vary; therefore, it is important for prescribers and pharmacists to understand the pharmacy practices in their state.

Where can medical providers find information on whether a biologic is an interchangeable biosimilar and other related information on FDA-approved biologics?
Medical providers and patients can find specific information related to biologics on the FDA Purple Book website. The Purple Book is an online database with information on FDA-approved biologics, including whether a specific biological product is a reference product, biosimilar, or interchangeable biosimilar. The Purple Book also provides links to the Prescribing Information (i.e., labeling), in addition to other information.